 - Bleeding diathesis including clinically significant platelet disorders or active hemoptysis defined as bright red blood of 12 teaspoon 2.5 mL in any 24 hour period within 6 months prior to study day 1. For clinically significant epistaxis within 4 weeks prior to study day 1, no risk of further bleeding must be clearly documented. 